ABPWW
Abpro Holdings Inc
Price Chart
No historical data available
Latest Quote
$0.01
Current Price| Open | $0.02 |
| Day High | $0.01 |
| Day Low | $0.01 |
| Volume | 70,000 |
Stock Information
| Total Debt | $294K |
| Cash Equivalents | $5.40M |
| Net Income | $-33K |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Income | $-33K |
| Book/sh | $-0.47 |
| Employees | 1 |
Financial Ratios
| Quick Ratio | 0.61 |
| Current Ratio | 0.73 |
Returns & Margins
| ROA | -83.15% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | -0.02 |
Analyst Data
| Recommendation | none |
Technical Indicators
| Shares Float | 4.95M |
| Volatility | 0.17 |
Performance History
| YTD | +0.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
No history data available. Data will be fetched automatically.
About Abpro Holdings Inc
Abpro Holdings, Inc., a biotechnology company, focuses on the development of novel antibodies using discovery and engineering platforms for immuno-oncology, ophthalmology, and infectious disease in the United States. Its platforms include DiversImmune, an antibody discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides flexibility to combine antibody building blocks in different combinations and orientations to create fit-for-purpose novel full-length multispecific antibody constructs. The company's lead product candidates include ABP-102, a next-generation immuno-oncology TetraBi antibody targeting HER2 and CD3 developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibits VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnerships with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | $183,000 | $122,000 | $2,029,000 |
| Operating Revenue | $183,000 | $122,000 | $2,029,000 |
| Expenses | |||
| Interest Expense | $387,000 | $23,000 | $248,000 |
| Total Expenses | $10,104,000 | $11,868,000 | $18,714,000 |
| Other Income Expense | $3,067,000 | - | - |
| Other Non Operating Income Expenses | $3,556,000 | - | - |
| Net Non Operating Interest Income Expense | $-378,000 | $40,000 | $-200,000 |
| Interest Expense Non Operating | $387,000 | $23,000 | $248,000 |
| Operating Expense | $10,104,000 | $11,868,000 | $18,714,000 |
| General And Administrative Expense | $7,121,000 | $7,602,000 | $8,960,000 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-7,232,000 | $-11,706,000 | $-17,215,000 |
| Net Interest Income | $-378,000 | $40,000 | $-200,000 |
| Interest Income | $9,000 | $63,000 | $48,000 |
| Normalized Income | $-6,743,000 | $-11,706,000 | $-17,215,000 |
| Net Income From Continuing And Discontinued Operation | $-7,232,000 | $-11,706,000 | $-17,215,000 |
| Total Operating Income As Reported | $-9,921,000 | $-11,746,000 | $-16,685,000 |
| Net Income Common Stockholders | $-17,409,000 | $-11,706,000 | $-17,215,000 |
| Net Income | $-7,232,000 | $-11,706,000 | $-17,215,000 |
| Net Income Including Noncontrolling Interests | $-7,232,000 | $-11,706,000 | $-17,215,000 |
| Net Income Continuous Operations | $-7,232,000 | $-11,706,000 | $-17,215,000 |
| Pretax Income | $-7,232,000 | $-11,706,000 | $-16,885,000 |
| Special Income Charges | $173,000 | $0 | - |
| Interest Income Non Operating | $9,000 | $63,000 | $48,000 |
| Operating Income | $-9,921,000 | $-11,746,000 | $-16,685,000 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,734,000 | $-10,891,000 | $-15,781,000 |
| Total Unusual Items | $-489,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $-489,000 | $0 | - |
| Reconciled Depreciation | $622,000 | $792,000 | $856,000 |
| EBITDA (Bullshit earnings) | $-6,223,000 | $-10,891,000 | $-15,781,000 |
| EBIT | $-6,845,000 | $-11,683,000 | $-16,637,000 |
| Diluted NI Availto Com Stockholders | $-17,409,000 | $-11,706,000 | $-17,215,000 |
| Otherunder Preferred Stock Dividend | $10,177,000 | $0 | - |
| Other Special Charges | $-173,000 | - | - |
| Gain On Sale Of Security | $-662,000 | - | - |
| Research And Development | $2,983,000 | $4,266,000 | $9,754,000 |
| Selling General And Administration | $7,121,000 | $7,602,000 | $8,960,000 |
| Other Gand A | $7,121,000 | $7,602,000 | $8,960,000 |
| Tax Provision | - | $0 | $330,000 |
Fetched: 2026-02-08
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $-15,671,000 | $-89,170,000 | $-76,479,000 |
| Total Assets | $4,661,000 | $3,355,000 | $11,852,000 |
| Total Non Current Assets | $885,000 | $1,320,000 | $2,205,000 |
| Non Current Prepaid Assets | $66,000 | $66,000 | $66,000 |
| Financial Assets | $188,000 | $0 | - |
| Goodwill And Other Intangible Assets | $176,000 | $186,000 | $196,000 |
| Other Intangible Assets | $176,000 | $186,000 | $196,000 |
| Current Assets | $3,776,000 | $2,035,000 | $9,647,000 |
| Other Current Assets | $306,000 | $208,000 | $292,000 |
| Hedging Assets Current | $155,000 | $0 | - |
| Current Deferred Assets | $0 | $878,000 | $0 |
| Restricted Cash | $142,000 | $138,000 | - |
| Receivables | $323,000 | $88,000 | $2,030,000 |
| Accounts Receivable | $323,000 | $88,000 | $2,030,000 |
| Cash Cash Equivalents And Short Term Investments | $2,850,000 | $723,000 | $7,325,000 |
| Cash And Cash Equivalents | $2,850,000 | $723,000 | $7,325,000 |
| Cash Financial | $2,850,000 | $723,000 | $7,325,000 |
| Other Non Current Assets | - | $138,000 | $137,000 |
| Non Current Note Receivables | - | $0 | $4,000 |
| Debt | |||
| Net Debt | $22,000 | $1,019,000 | - |
| Total Debt | $3,328,000 | $2,894,000 | $1,874,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $455,000 | $1,119,000 |
| Current Debt And Capital Lease Obligation | $3,328,000 | $2,439,000 | $755,000 |
| Current Debt | $2,872,000 | $1,742,000 | - |
| Other Current Borrowings | $2,725,000 | - | - |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $19,607,000 | $91,790,000 | $87,586,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $76,054,000 | $76,718,000 |
| Current Liabilities | $19,607,000 | $15,736,000 | $10,868,000 |
| Other Current Liabilities | $80,000 | - | - |
| Current Notes Payable | $147,000 | $1,742,000 | $0 |
| Payables And Accrued Expenses | $16,199,000 | $13,297,000 | $10,049,000 |
| Interest Payable | $267,000 | - | - |
| Payables | $8,703,000 | $7,916,000 | $8,152,000 |
| Total Tax Payable | $4,767,000 | $0 | - |
| Income Tax Payable | $366,000 | $0 | - |
| Accounts Payable | $3,936,000 | $7,916,000 | $8,152,000 |
| Current Deferred Liabilities | - | $0 | $64,000 |
| Equity | |||
| Common Stock Equity | $-15,495,000 | $-88,984,000 | $-76,283,000 |
| Total Equity Gross Minority Interest | $-14,946,000 | $-88,435,000 | $-75,734,000 |
| Stockholders Equity | $-15,495,000 | $-88,984,000 | $-76,283,000 |
| Retained Earnings | $-116,103,000 | $-108,871,000 | $-93,865,000 |
| Preferred Securities Outside Stock Equity | $0 | $75,599,000 | $75,599,000 |
| Other | |||
| Treasury Shares Number | $983,333 | - | - |
| Ordinary Shares Number | $50,832,432 | $50,535,272 | $50,535,272 |
| Share Issued | $51,815,765 | $50,535,272 | $50,535,272 |
| Tangible Book Value | $-15,671,000 | $-89,170,000 | $-76,479,000 |
| Invested Capital | $-12,623,000 | $-87,242,000 | $-76,283,000 |
| Working Capital | $-15,831,000 | $-13,701,000 | $-1,221,000 |
| Capital Lease Obligations | $456,000 | $1,152,000 | $1,874,000 |
| Total Capitalization | $-15,495,000 | $-88,984,000 | $-76,283,000 |
| Minority Interest | $549,000 | $549,000 | $549,000 |
| Treasury Stock | $0 | $33,000 | $33,000 |
| Additional Paid In Capital | $100,603,000 | $19,918,000 | $17,606,000 |
| Capital Stock | $5,000 | $2,000 | $9,000 |
| Common Stock | $5,000 | $2,000 | $9,000 |
| Long Term Capital Lease Obligation | $0 | $455,000 | $1,119,000 |
| Current Capital Lease Obligation | $456,000 | $697,000 | $755,000 |
| Current Accrued Expenses | $7,496,000 | $5,381,000 | $1,897,000 |
| Net PPE | $455,000 | $1,068,000 | $1,802,000 |
| Accumulated Depreciation | $-2,656,000 | $-2,591,000 | $-2,322,000 |
| Gross PPE | $3,111,000 | $3,659,000 | $4,124,000 |
| Leases | $788,000 | $788,000 | $788,000 |
| Other Properties | $2,255,000 | $2,803,000 | $3,268,000 |
| Machinery Furniture Equipment | $68,000 | $68,000 | $68,000 |
| Properties | $0 | $0 | $0 |
| Current Deferred Revenue | - | $0 | $64,000 |
Fetched: 2026-02-08
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-9,030,000 | $-7,450,000 | $-9,017,000 |
| Operating Activities | |||
| Operating Cash Flow | $-9,030,000 | $-7,402,000 | $-8,952,000 |
| Cash Flow From Continuing Operating Activities | $-9,030,000 | $-7,402,000 | $-8,952,000 |
| Operating Gains Losses | $177,000 | - | - |
| Investing Activities | |||
| Investing Cash Flow | $0 | $-48,000 | $-65,000 |
| Cash Flow From Continuing Investing Activities | $0 | $-48,000 | $-65,000 |
| Capital Expenditure | - | $-48,000 | $-65,000 |
| Financing Activities | |||
| Issuance Of Capital Stock | $10,361,000 | $0 | $9,991,000 |
| Financing Cash Flow | $11,161,000 | $849,000 | $9,784,000 |
| Cash Flow From Continuing Financing Activities | $11,161,000 | $849,000 | $9,784,000 |
| Net Other Financing Charges | $-952,000 | $-371,000 | - |
| Net Common Stock Issuance | $10,361,000 | $0 | - |
| Common Stock Issuance | $10,361,000 | $0 | - |
| Net Preferred Stock Issuance | - | $0 | $9,991,000 |
| Preferred Stock Issuance | - | $0 | $9,991,000 |
| Other | |||
| Repayment Of Debt | $-5,752,000 | $-222,000 | $-207,000 |
| Issuance Of Debt | $8,638,000 | $1,442,000 | $0 |
| Interest Paid Supplemental Data | $1,000 | $16,000 | $30,000 |
| End Cash Position | $2,992,000 | $861,000 | $7,462,000 |
| Beginning Cash Position | $861,000 | $7,462,000 | $6,695,000 |
| Changes In Cash | $2,131,000 | $-6,601,000 | $767,000 |
| Proceeds From Stock Option Exercised | $-1,134,000 | $0 | - |
| Net Issuance Payments Of Debt | $2,886,000 | $1,220,000 | $-207,000 |
| Net Short Term Debt Issuance | $2,903,000 | $1,442,000 | $0 |
| Short Term Debt Payments | $-5,735,000 | $0 | - |
| Short Term Debt Issuance | $8,638,000 | $1,442,000 | $0 |
| Net Long Term Debt Issuance | $-17,000 | $-222,000 | $-207,000 |
| Long Term Debt Payments | $-17,000 | $-222,000 | $-207,000 |
| Net PPE Purchase And Sale | $0 | $-48,000 | $0 |
| Purchase Of PPE | $0 | $-48,000 | $0 |
| Change In Working Capital | $-1,319,000 | $1,207,000 | $3,389,000 |
| Change In Other Current Liabilities | $-566,000 | $-500,000 | $-440,000 |
| Change In Payables And Accrued Expense | $-420,000 | $-259,000 | $5,790,000 |
| Change In Accrued Expense | $383,000 | $484,000 | $-454,000 |
| Change In Payable | $-803,000 | $-743,000 | $6,244,000 |
| Change In Account Payable | $-860,000 | $-743,000 | $6,244,000 |
| Change In Tax Payable | $57,000 | $0 | - |
| Change In Income Tax Payable | $57,000 | $0 | - |
| Change In Prepaid Assets | $-98,000 | $84,000 | $-35,000 |
| Change In Receivables | $-235,000 | $1,946,000 | $-1,990,000 |
| Changes In Account Receivables | $-235,000 | $1,942,000 | $-1,990,000 |
| Other Non Cash Items | $-3,205,000 | - | - |
| Stock Based Compensation | $1,927,000 | $2,305,000 | $4,018,000 |
| Depreciation Amortization Depletion | $622,000 | $792,000 | $856,000 |
| Depreciation And Amortization | $622,000 | $792,000 | $856,000 |
| Depreciation | $622,000 | $792,000 | $856,000 |
| Gain Loss On Investment Securities | $350,000 | - | - |
| Net Income From Continuing Operations | $-7,232,000 | $-11,706,000 | $-17,215,000 |
| Net Intangibles Purchase And Sale | - | $0 | $-65,000 |
| Purchase Of Intangibles | - | $0 | $-65,000 |
| Change In Other Working Capital | - | $-64,000 | $64,000 |
Fetched: 2026-02-08